Heron Therapeutics
HRTX
176 hedge funds and large institutions have $2.37B invested in Heron Therapeutics in 2018 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 69 increasing their positions, 60 reducing their positions, and 41 closing their positions.
84% more call options, than puts
Call options by funds: $7.3M | Put options by funds: $3.97M
15% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 60
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
4.51% more ownership
Funds ownership: 112.57% → 117.09% (+4.5%)
9% less funds holding
Funds holding: 194 → 176 (-18)
14% less capital invested
Capital invested by funds: $2.77B → $2.37B (-$401M)
44% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$70.5M |
| 2 |
ClearBridge Investments
New York
|
+$23.7M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$22.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$20.8M |
| 5 |
NC
Nexthera Capital
New York
|
+$20.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$42.7M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$22.6M |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$21.9M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$19M |
| 5 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
-$10.3M |
HRTX Hedge Fund Activity: Q4 2018 in Review
176 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2018, worth a combined $2.37B — down 14% from $2.77B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of HRTX and 23 opened new positions — a net loss of 18 holders — while 60 trimmed existing stakes and 69 added.
The largest buyer was Franklin Resources, adding an estimated $70.5M. The largest seller was Fidelity Investments, cutting an estimated $42.7M.
- 176 institutional investors held Heron Therapeutics (HRTX) as of Q4 2018, down from 194 in Q3 2018.
- Funds reported $2.37B of Heron Therapeutics stock for Q4 2018, down 14% quarter-over-quarter.
- 23 funds opened new Heron Therapeutics positions in Q4 2018 and 41 closed out, a net change of -18 holders.
- The largest Heron Therapeutics buyer in Q4 2018 was Franklin Resources, an estimated $70.5M added.
- The largest Heron Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $42.7M sold.
Based on aggregated 13F filings for Q4 2018.